To test the hypothesis that the modification of platelet behavior might reduce the incidence of ischemic deficits following surgery for subarachnoid hemorrhage.
- Dipyridamole (Persantine®)Drug
Intervention Desc: Platelet aggregation inhibitor
Single-blind, controlled trial of 677 patients.
Patients were randomized immediately upon admission to receive either placebo or dipyridamole 100 mg/day orally or 10 mg/day intravenously. Patients who underwent surgery continued the treatment for 3 months postoperatively.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Glasgow Outcome Scale and specific neurological deficits at 3 months postoperatively.|